SI-Bone price target raised to $19 from $15 at Morgan Stanley

Morgan Stanley raised the firm’s price target on SI-Bone (SIBN) to $19 from $15 and keeps an Overweight rating on the shares. Q2 sales were known following January’s preannouncement, but 2025 revenue guidance tracked largely in-line with buyside estimates and messaging around adjusted EBITDA was “probably a tad better than expected,” the analyst tells investors. The firm thinks the guidance framework is conservative and sees “a path for sustainable beats and raises through the year both on the top and bottom line,” the analyst added.